; and (C) by adding at the end the following new paragraph: (10) Cost-sharing for chronic care drugs (A) In general For plan years beginning on or after January 1, 2025, in the case of a chronic care drug, the following shall apply: (i) For costs below the annual deductible specified in paragraph (1), cost-sharing for such drug shall not exceed the net price of such drug. (ii) Subject to subparagraph (B), for costs above the annual deductible specified in paragraph (1) and below the out-of-pocket threshold specified in paragraph (4), any coinsurance amount for such drug shall be based on a percentage of the net price of such drug. (B) Exception The requirement under subparagraph (A)(ii) shall not apply to a chronic care drug under a prescription drug plan if the cost-sharing amount for such drug under such plan is based on a copayment that is not tied to a percentage of a drug price (such as the negotiated price, list price, or wholesale acquisition cost), a drug benchmark price (such as the average wholesale price), or a drug cost. (C) Definitions In this paragraph: (i) Chronic care drug The term chronic care drug means a covered part D drug that is included under any of the following United States Pharmacopeia Convention (USP) categories and classes of drugs, as included in the most recent version of the USP Medicare Model Guidelines: (I) Blood glucose regulators, other than insulins. (II) Anti-inflammatories, inhaled corticosteroids. (III) Bronchodilators, anticholinergic. (IV) Bronchodilators, sympathomimetic. (V) Respiratory tract agents, other. (VI) Anticoagulants. (VII) Cardiovascular agents, other. (VIII) Any category or class identified by the Secretary or USP as a successor to the categories and classes described in subclauses (I) through (VII) based on the most recent USP Medicare Model Guidelines at the time of such identification. (ii) Net price The term net price means the negotiated price of the drug net of all price concessions originating from manufacturers that are received or expected to be